Spots Global Cancer Trial Database for induction therapy
Every month we try and update this database with for induction therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer | NCT00923845 | Renal Cell Carc... Graft-Versus-Ho... Engraftment Syn... | Pentostatin Sirolimus Cyclophosphamid... Allogeneic Hema... Th2 rapa cells Donor Lymphocyt... Induction Thera... GVHD prophylaxi... Donor Hematopoi... | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM) | NCT01341262 | Multiple Myelom... | Thalidomide Dexamethasone Zoledronic acid Cyclophosphamid... Melphalan | 18 Years - 65 Years | IRCCS Azienda Ospedaliero-Universitaria di Bologna | |
| Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors | NCT05758389 | Head and Neck T... | Tislelizumab, P... | 18 Years - 75 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | NCT02632708 | Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft... | AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide | 18 Years - | Servier | |
| Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma | NCT02655458 | Multiple Myelom... | Elotuzumab Lenalidomide autologous PBMC... ASCT | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer | NCT00176267 | Squamous Cell C... | Radiotherapy Paclitaxel Carboplatin | 18 Years - | University of Kentucky | |
| Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients | NCT00382694 | Multiple Myelom... | Fludarabine | 18 Years - 64 Years | Nordic Myeloma Study Group | |
| Optimum Induction Therapy of Low-risk APL | NCT05832320 | Acute Promyeloc... Induction Thera... Oral | Etoposide Daunorubicin | 18 Years - 75 Years | Peking University People's Hospital | |
| Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option | NCT04926584 | Carcinoma, Non-... | induction thera... | 18 Years - | Klinikum Esslingen | |
| A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy | NCT00833560 | Multiple Myelom... | Cyclophosphamid... Bortezomib Dexamethasone | 18 Years - 60 Years | Janssen-Cilag G.m.b.H | |
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | NCT02632708 | Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft... | AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide | 18 Years - | Servier | |
| Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia | NCT01960387 | Acute Myeloid L... | Clofarabine Cytarabine | 18 Years - | University of Pittsburgh | |
| RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC | NCT04849377 | Human Papilloma... Head and Neck S... | RT 50 Gy RT 54 GY RT 60 GY Induction Thera... Carboplatin Cisplatin 200 Cisplatin 240 | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB | NCT02326285 | Non-squamous No... Non-squamous No... Non-squamous No... Activating EGFR... NSCLC | Gefitinib docetaxel cisplatin Surgery | 18 Years - | AIO-Studien-gGmbH | |
| Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia | NCT01960387 | Acute Myeloid L... | Clofarabine Cytarabine | 18 Years - | University of Pittsburgh | |
| Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB | NCT02326285 | Non-squamous No... Non-squamous No... Non-squamous No... Activating EGFR... NSCLC | Gefitinib docetaxel cisplatin Surgery | 18 Years - | AIO-Studien-gGmbH | |
| Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma | NCT05151588 | Sinonasal Carci... | Docetaxel Cis Platinum 5-FU Tazemetostat Surgery Chemoradiation | 18 Years - | The University of Hong Kong | |
| Frontline Therapy in de Novo Multiple Myeloma Patients Under 65 | NCT01206205 | Multiple Myelom... | Lenalidomide, B... | 18 Years - 65 Years | University Hospital, Toulouse | |
| Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL | NCT05557110 | B Acute Lymphob... | Blinatumomab | 15 Years - 65 Years | The First Affiliated Hospital of Soochow University | |
| Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma | NCT02655458 | Multiple Myelom... | Elotuzumab Lenalidomide autologous PBMC... ASCT | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. | NCT00801281 | Follicular Lymp... Marginal Zone L... Small Lymphocyt... Lymphoplasmacyt... | Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone 1 Prednisone 2 | 18 Years - | Polish Lymphoma Research Group | |
| Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer | NCT00176267 | Squamous Cell C... | Radiotherapy Paclitaxel Carboplatin | 18 Years - | University of Kentucky | |
| Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer | NCT06421376 | Esophageal Canc... Immunotherapy Induction Thera... Chemoradiothera... Surgery | Cardonilizumab Chemoradiothera... Radical surgery | 18 Years - 80 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. | NCT00801281 | Follicular Lymp... Marginal Zone L... Small Lymphocyt... Lymphoplasmacyt... | Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone 1 Prednisone 2 | 18 Years - | Polish Lymphoma Research Group | |
| Safety and Efficacy of APG-157 in Head and Neck Cancer | NCT05312710 | Head and Neck C... Squamous Cell C... Squamous Cell C... | APG-157 | 18 Years - | Aveta Biomics, Inc. | |
| Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients | NCT00382694 | Multiple Myelom... | Fludarabine | 18 Years - 64 Years | Nordic Myeloma Study Group | |
| First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. | NCT00801281 | Follicular Lymp... Marginal Zone L... Small Lymphocyt... Lymphoplasmacyt... | Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone 1 Prednisone 2 | 18 Years - | Polish Lymphoma Research Group | |
| Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer | NCT00176254 | Squamous Cell C... | Radiotherapy Paclitaxel Carboplatin | 18 Years - | University of Kentucky | |
| Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors | NCT05758389 | Head and Neck T... | Tislelizumab, P... | 18 Years - 75 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Autologous Stem Cell Transplantation for Patients With AL Amyloidosis | NCT04210791 | AL Amyloidosis Plasma Cell Dys... | 18 Years - 75 Years | Nanjing University School of Medicine | ||
| Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients | NCT05471700 | Leukemia, Myelo... | Azacitidine Venetoclax | 45 Years - 65 Years | Zhujiang Hospital | |
| Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy | NCT02891811 | Multiple Myelom... | Carfilzomib Thalidomide Lenalidomide Dexamethasone | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma | NCT03224507 | Multiple Myelom... | KRdD followed b... KRdD only | 18 Years - | University of Alabama at Birmingham |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
